BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics

A biotechnology company that develops stem cell therapies for the treatment of neurodegenerative diseases

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

July 27, 2012
BrainStorm Cell Therapeutics raises a $206,910 seed round.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
BrainStorm Cell Therapeutics seed round
206,910
July 27, 2012
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Adrian Harel

Employee

Liat Soffer

Employee

Further reading

Title
Author
Link
Type
Date

BrainStorm Cell Therapeutics halfCway through enrolling its Phase 3 ALS study

Christine Corrado

Web

Documentaries, videos and podcasts

Title
Date
Link

BrainStorm Cell Therapeutics

April 27, 2018

BrainStorm Cell Therapeutics halfway through enrolling its Phase 3 ALS study

January 11, 2019

Brainstorm Cell Therapeutics updates on its progressive MS drug development trials

February 12, 2019

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Pomerantz LLP
March 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ:...
Pomerantz LLP
February 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ:...
Brandon May
November 17, 2020
BioSpace
A Phase III trial of NurOwn® (MSC-NTF cells), BrainStorm Cell Therapeutics' investigational therapy for amyotrophic lateral sclerosis, did not find a statistically significant difference between the therapy and placebo for improving scores on a revised ALS functional rating scale.
Brian Barrett
June 23, 2020
Wired
At 37, Brian Wallach was diagnosed with the fatal disease. So he tapped a lifetime of connections to give help and hope to fellow sufferers--while grappling with his own mortality.
BioSpace
June 9, 2020
BioSpace
The ALS Association and I AM ALS announced that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics, a biotechnology company, to support an amyotrophic lateral sclerosis biomarker research study.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.